M. Barletta
University of Georgia(US)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Gastric Cancer Management and Outcomes, Hepatocellular Carcinoma Treatment and Prognosis, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers(2012)71 cited
- → A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients(2008)65 cited
- → Discovery, Biological Evaluation, and Structure–Activity and −Selectivity Relationships of 6′-Substituted (E)-2-(Benzofuran-3(2H)-ylidene)-N-methylacetamides, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors(2013)60 cited
- → Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9(2012)47 cited
- → METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER(2010)30 cited
- → The influence of positional isomerism on G-quadruplex binding and anti-proliferative activity of tetra-substituted naphthalene diimide compounds(2013)20 cited
- → A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients(2022)11 cited
- → Discordant Somatic and Germline VEGF-A Genotype in a Cancer Patient Resistant to Paclitaxel/Bevacizumab with Chemosensitive Hepatic Metastasis(2009)7 cited
- → Some pharmacological aspects of a new water-soluble tetracycline(1964)5 cited
- → The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)(2007)4 cited